Ionis Pharmaceuticals Stock Slides 37% Over 6 Straight Down Days
A six-day slide in the biotech’s stock prompts a closer look at the numbers behind the momentum.
Ionis Pharmaceuticals (IONS) stock has now moved lower for 6 consecutive trading days, a cumulative loss of 36.6%. The streak has erased about $5.2 billion from the company’s market value, which now stands at about $9.0 billion.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
How The Streak Stacks Up Against The S&P 500
- A 9-Day Losing Streak Has Quest Diagnostics Stock Down 6.2%
- 6 Red Days In A Row: Arrowhead Pharmaceuticals Stock Is Down 17%
- Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14%
- CoreWeave Stock Extends A 5-Day Losing Streak To A 14% Loss
- Planet Labs PBC Stock Slides 25% Over 10 Straight Down Days
- Capital One Financial Stock Climbs 8.8% On A 5-Day Winning Streak
Here is how IONS stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | IONS | S&P 500 |
|---|---|---|
| 1D | -0.4% | 0.4% |
| 6D (Current Streak) | -36.6% | 0.9% |
| 1M (21D) | -25.3% | 1.9% |
| 3M (63D) | -28.7% | 8.7% |
| YTD 2026 | -30.8% | 10.6% |
| 2025 | 126.3% | 16.4% |
| 2024 | -30.9% | 23.3% |
| 2023 | 33.9% | 24.2% |
Are the fundamentals justifying the pressure?
The data suggests the market may be weighing some operational strains. Ionis shows an operating margin of -33.3% over the last twelve months, against an S&P 500 median of 18.4%. This move is also specific to the stock; the S&P 500 returned +0.9% over the same period. While such streaks draw attention, they are not unique, with 34 S&P 500 stocks currently on losing streaks of 3 days or more.
A streak is a question, not an answer.
A persistent move in a stock is information. It signals that market attention and momentum are focused, but it is not an instruction to buy or sell. For the disciplined investor, a streak is a prompt to check the business against the price. The numbers here provide a clear starting point for that work, framing the stock’s recent performance against its underlying financial metrics.
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
Prefer the theme to this single name? Our ETF Scorecard shows how the biotech funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
A Slide Like This Is Why Diversification Exists
Watching one stock fall day after day is the clearest lesson the market teaches about single-name risk. Whether this particular decline is an opportunity or a warning, the deeper point is the same: no one name should be able to do this to your portfolio.
The Trefis High Quality (HQ) Portfolio is built on that principle: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Study the slide; spread the risk.